OPK

Peers: DGX FLGT LH NEO MYGN MDXH XGN ARDX ASND PFE

| Held by: IWM VTI VB VXF IWN IBB VTWO SCHA VBR VBK

Index	RUT
Market Cap	1.24B
Enterprise Value	1.33B
Income	-72.89M
Sales	587.89M
Book/sh	1.59
Cash/sh	0.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2275
IPO	Nov 02, 1995

P/E	-
Forward P/E	-
PEG	-
P/S	2.10
P/B	1.04
P/C	4.11
P/FCF	-
EV/EBITDA	-
EV/Sales	2.27
Quick Ratio	2.93
Current Ratio	3.35
Debt/Eq	0.34
LT Debt/Eq	0.32
Option/Short	Yes / Yes

EPS (ttm)	-0.10
EPS next Y	-0.30
EPS next Q	-0.07
EPS this Y	24.44%
EPS next Y	-34.56%
EPS next 5Y	6.53%
EPS past 3/5Y	13.03% -
Sales past 3/5Y	-15.45% -15.82%
EPS Y/Y TTM	58.54%
Sales Y/Y TTM	-11.46%
EPS Q/Q	94.11%
Sales Q/Q	4.32%
Earnings	Jul 27 AMC
EPS/Sales Surpr.	87.50% 24.59%

Insider Own	48.59%
Insider Trans	0.00%
Inst Own	28.87%
Inst Trans	1.38%
ROA	-3.83%
ROE	-5.88%
ROIC	-4.67%
Gross Margin	27.75%
Oper. Margin	-28.56%
Profit Margin	-12.40%
SMA20	8.44%
SMA50	7.07%
SMA200	23.72%
Trades

Shs Outstand	745.95M
Shs Float	383.72M
Short Float	9.27%
Short Ratio	8.47
Short Interest	35.56M
52W High	1.77 -6.50%
52W Low	0.98 69.41%
Volatility	5.11% 5.26%
ATR (14)	0.09
RSI (14)	58.49
Beta	1.52
Rel Volume	0.35
Avg Volume	4.20M
Volume	573,165

Perf Week	2.80%
Perf Month	0.91%
Perf Quarter	0.30%
Perf Half Y	37.92%
Perf YTD	31.35%
Perf Year	10.33%
Perf 3Y	31.35%
Perf 5Y	-54.03%
Perf 10Y	-82.13%
Recom	1.33
Target Price	4.15
Prev Close	1.63
Price	1.65
Change %	1.53%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-26	Upgrade	Barrington Research	Mkt Perform → Outperform	$2.25
Apr-29-26	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-20-25	Initiated	JP Morgan	Neutral
Oct-31-25	Downgrade	Jefferies	Buy → Hold	$1.60
Apr-25-25	Initiated	JP Morgan	Neutral
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform	$2
Dec-15-22	Initiated	H.C. Wainwright	Buy	$3
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy	$7
Nov-25-19	Initiated	Piper Jaffray	Overweight	$2.50
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy	$16 → $18
Jun-03-16	Initiated	Standpoint Research	Buy	$16
Mar-31-16	Reiterated	Barrington Research	Outperform	$17 → $16
Oct-16-15	Initiated	JP Morgan	Overweight	$14
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform	$13 → $12
Mar-14-14	Initiated	Oppenheimer	Outperform	$13

Show Previous Ratings

Today 10:57AM	Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching? (FinanceWire)
Oct-15-26 12:11PM	Labcorp outlays up to $872m to acquire BioReferences laboratory assets (Medical Device Network) +17.52%
11:18AM	Labcorp to buy BioReference assets for up to $872M (MedTech Dive)
09:45AM	Opko Health stock soars on $722M BioReference asset sale (Investing.com)
07:30AM	Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health (PR Newswire)
01:55PM	Loading…
Sep-08-26 01:55PM	OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
Aug-31-26 11:39AM	Cocrystal Pharma: The Strategic Reset Investors May Be Missing (Exec Edge)
Aug-13-26 09:15AM	OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests (GlobeNewswire)
Jul-28-26 01:01AM	OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ... (GuruFocus.com) +33.06%
Jul-27-26 04:18PM	OPKO Health: Q2 Earnings Snapshot (Associated Press)
04:05PM	OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results (GlobeNewswire)
Jul-23-26 12:30PM	OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026 (GlobeNewswire)
Jun-15-26 08:00AM	Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026 (GlobeNewswire)
May-12-26 08:00AM	OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies (GlobeNewswire)
Apr-30-26 08:30AM	OPKO Health Expands Nicoya Agreement to Support RAYALDEE Commercialization in Greater China (GlobeNewswire)
08:00AM	Loading…
08:00AM	BioReference Launches BioReference Direct, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform (GlobeNewswire)
Apr-29-26 03:09AM	OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... (GuruFocus.com) -8.26%
Apr-28-26 04:48PM	OPKO Health: Q1 Earnings Snapshot (Associated Press)
04:05PM	OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results (GlobeNewswire)
Apr-22-26 08:00AM	OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas (GlobeNewswire)
Apr-21-26 04:05PM	OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 (GlobeNewswire)
Apr-08-26 08:00AM	OPKO Health's ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 (GlobeNewswire)
Feb-27-26 12:48PM	OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts (Zacks)
08:00AM	OPKO Health to Participate in the Jefferies Biotech on the Beach Summit (GlobeNewswire)
01:12AM	OPKO Health Q4 Earnings Call Highlights (MarketBeat)
12:06AM	OPKO Health Inc (OPK) Q4 2025 Earnings Call Highlights: Strategic Divestitures and Promising ... (GuruFocus.com)
Feb-26-26 07:00PM	Compared to Estimates, OPKO Health (OPK) Q4 Earnings: A Look at Key Metrics (Zacks)
06:45PM	OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:34PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
10:39AM	Loading…
Feb-18-26 10:39AM	Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? (Zacks)
Feb-17-26 08:42PM	Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation (Insider Monkey)
Feb-12-26 08:00AM	OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 (GlobeNewswire)
Feb-06-26 11:02AM	Opko Health (OPK) Expands Entera Partnership for Drug Co-Development (Insider Monkey)
Feb-04-26 08:00AM	OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism (GlobeNewswire)
Jan-13-26 04:43AM	OrthoPediatrics (KIDS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Jan-06-26 04:11PM	OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
07:05AM	OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth (Zacks)
Dec-09-25 07:28AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now (Zacks)
Nov-20-25 09:40AM	Astera initiated, Nasdaq upgraded: Wall Street's top analyst calls (The Fly)
Nov-19-25 04:05PM	OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 08:03AM	NextPlat Reports Third Quarter 2025 Results (PR Newswire)
Oct-30-25 11:29PM	Opko Health Inc.'s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals (Insider Monkey) -6.85%
12:24PM	OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands (Zacks)
Oct-29-25 06:30PM	Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics (Zacks)
05:40PM	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
04:42PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications (GlobeNewswire)
Oct-28-25 08:00AM	OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers (GlobeNewswire)
Oct-23-25 01:56PM	Here's Why You Should Add OPKO Health Stock to Your Portfolio (Zacks)
Oct-22-25 04:05PM	OPKO Health to Report Third Quarter 2025 Financial Results on October 29 (GlobeNewswire)
Oct-01-25 01:44PM	OPKO Health, Inc. (OPK)'s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1 (Insider Monkey)
Sep-17-25 08:52AM	LH Stock Rises on Acquisition of BioReference Health's Select Assets (Zacks)
Sep-15-25 08:30AM	Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Sep-11-25 12:20PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Aug-17-25 06:23PM	OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics (Insider Monkey)
Aug-08-25 04:05PM	Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-06-25 03:27PM	RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment. (Barrons.com)
Aug-04-25 10:01AM	Opko Health (OPK) Reports Fiscal Q2 2025 Results (Insider Monkey) +6.72%
Aug-01-25 12:20PM	OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands (Zacks) -7.03%
06:47AM	OPKO Health (OPK) to Present Short Bowel Syndrome Treatment in Prague (Insider Monkey)
Jul-31-25 07:00PM	Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics (Zacks)
05:45PM	OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:45PM	OPKO Health: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Jul-24-25 04:05PM	OPKO Health to Report Second Quarter 2025 Financial Results on July 31 (GlobeNewswire)
Jul-23-25 11:25AM	OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) (Insider Monkey)
Jul-08-25 08:00AM	OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress (GlobeNewswire)
Jul-07-25 09:10AM	H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 (Insider Monkey)
Jun-25-25 11:00AM	OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium (GlobeNewswire)
08:00AM	OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting (GlobeNewswire)
Jun-24-25 03:52PM	Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT (Insider Monkey)
Jun-13-25 12:37PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Jun-09-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development (GlobeNewswire)
May-15-25 08:00AM	OPKO Health to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-01-25 12:43PM	OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands (Zacks)
08:57AM	Q1 2025 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:17AM	OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Apr-30-25 07:52PM	OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:50PM	OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	OPKO Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Apr-22-25 09:35AM	Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround (Zacks)
Apr-17-25 09:38AM	Labcorp Holdings: Regaining Credibility (Seeking Alpha)
08:00AM	OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 (GlobeNewswire)
Apr-11-25 04:05PM	NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program (PR Newswire)
Apr-04-25 08:00AM	OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program (GlobeNewswire)
Mar-28-25 09:35AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Mar-18-25 11:37AM	Opko and Entera focus on oral care for obesity and metabolic disorders (Pharmaceutical Technology)
Mar-17-25 08:00AM	OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders (GlobeNewswire)
Mar-14-25 06:59PM	Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. (Barrons.com)
12:07PM	Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? (Insider Monkey)
Mar-12-25 12:10PM	Labcorp to acquire certain assets of Opko Healths BioReference Health (TipRanks)
11:06AM	Truist remains bullish on Labcorp after another nice strategic acquisition (TipRanks)
Mar-11-25 07:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Feb-28-25 09:01AM	Q4 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.75%
02:35AM	OPKO Health Inc (OPK) Q4 2024 Earnings Call Highlights: Strong Pharmaceutical Growth and ... (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PAGANELLI JOHN A	Director	Mar 20 '26	Buy	1.14	10,000	11,350	394,340	Mar 20 04:25 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 21 '25	Buy	1.33	580,000	768,807	216,706,448	Nov 21 05:07 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 20 '25	Buy	1.33	580,000	771,328	216,126,448	Nov 20 06:10 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 19 '25	Buy	1.31	580,000	759,115	215,546,448	Nov 19 05:02 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 18 '25	Buy	1.27	533,300	678,906	214,966,448	Nov 18 05:18 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Oct 31 '25	Buy	1.42	150,000	213,435	214,386,448	Oct 31 05:15 PM

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment manages the clinical laboratory operations of BioReference. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and their global pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Ph.D.Dr. Phillip Frost M.D.

Ph.D.Dr. Jane H. Hsiao M.B.A.

President & Vice Chairman of the BoardDr. Elias Adam Zerhouni M.D.

Senior VPMr. Adam E. Logal

J.D.Mr. Steven D. Rubin Esq.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Opko Health Inc

Upgrade your Finviz experience